Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection

New England Journal of Medicine

Volumn 376, Issue 22, 2017, Pages 2134-2146

  Bourlière, Marc ^a   Gordon, Stuart C ^c   Flamm, Steven L ^d   Cooper, Curtis L ^e   Ramji, Alnoor ^f   Tong, Myron ^g   Ravendhran, Natarajan ^j   Vierling, John M ^k   Tran, Tram T ^h   Pianko, Stephen ^l   Bansal, Meena B ⁿ   De Lédinghen, Victor ^b   Hyland, Robert H ⁱ   Stamm, Luisa M ⁱ   Dvory Sobol, Hadas ⁱ   Svarovskaia, Evguenia ⁱ   Zhang, Jie ⁱ   Huang, K C ⁱ   Subramanian, G Mani ⁱ   Brainard, Diana M ⁱ   McHutchison, John G ⁱ   Verna, Elizabeth C ^o   Buggisch, Peter ^p   Landis, Charles S ^s   Younes, Ziad H ^u   Curry, Michael P ^v   Strasser, Simone I ^m   Schiff, Eugene R ^w   Reddy, K Rajender ^x   Manns, Michael P ^q   Kowdley, Kris V ^t   Zeuzem, Stefan ^r   more..

^a HÔPITAL SAINT JOSEPH   (France)

^b BORDEAUX UNIVERSITY HOSPITAL   (France)

^c HENRY FORD HEALTH SYSTEM   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^f ST PAUL S HOSPITAL   (Canada)

^g HUNTINGTON MEDICAL RESEARCH INSTITUTES   (United States)

^h CEDARS SINAI MEDICAL CENTER   (United States)

ⁱ GILEAD SCIENCES   (United States)

^j Digestive Diseases Associates   (United States)

^k BAYLOR COLLEGE OF MEDICINE   (United States)

^l SOUTHERN HEALTH   (Australia)

^m ROYAL PRINCE ALFRED HOSPITAL   (Australia)

ⁿ MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^o NewYork Presbyterian Hospital   (United States)

^p Ifi Institute for Interdisciplinary Medicine   (Germany)

^q HANNOVER MEDICAL SCHOOL   (Germany)

^r UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^s UNIVERSITY OF WASHINGTON   (United States)

^t SWEDISH MEDICAL CENTER   (United States)

^u Gastro One   (United States)

^v BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^w UNIVERSITY OF MIAMI   (United States)

^x UNIVERSITY OF PENNSYLVANIA   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; PLACEBO; SOFOSBUVIR PLUS VELPATASVIR; SOFOSBUVIR PLUS VELPATASVIR PLUS VOXILAPREVIR; UNCLASSIFIED DRUG; CARBAMIC ACID DERIVATIVE; DRUG COMBINATION; FUSED HETEROCYCLIC RINGS; MACROCYCLIC COMPOUND; NS-5 PROTEIN, HEPATITIS C VIRUS; PROTEINASE INHIBITOR; SOFOSBUVIR; SULFONAMIDE; VELPATASVIR; VIRAL PROTEIN; VOXILAPREVIR;

ABDOMINAL PAIN; ABNORMAL LABORATORY RESULT; ADULT; AGED; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; CONTROLLED STUDY; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; GEOGRAPHIC DISTRIBUTION; HEADACHE; HEPATITIS C; HUMAN; INSOMNIA; IRRITABILITY; LIMIT OF QUANTITATION; MAJOR CLINICAL STUDY; MALE; NAUSEA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; SEQUENCE ALIGNMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE; ANTAGONISTS AND INHIBITORS; ANTIVIRAL RESISTANCE; CLINICAL TRIAL; COMPLICATION; DRUG COMBINATION; DRUG EFFECTS; GENETICS; HEPACIVIRUS; LIVER CIRRHOSIS; MIDDLE AGED; MULTICENTER STUDY; PHASE 3 CLINICAL TRIAL; RANDOMIZED CONTROLLED TRIAL; VERY ELDERLY; VIROLOGY;

ADULT; AGED; AGED, 80 AND OVER; ANTIVIRAL AGENTS; CARBAMATES; DRUG COMBINATIONS; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPACIVIRUS; HEPATITIS C; HETEROCYCLIC COMPOUNDS, 4 OR MORE RINGS; HUMANS; LIVER CIRRHOSIS; MACROCYCLIC COMPOUNDS; MALE; MIDDLE AGED; PROTEASE INHIBITORS; SOFOSBUVIR; SULFONAMIDES; VIRAL NONSTRUCTURAL PROTEINS;

EID: 85020200062     PISSN: 00284793     EISSN: 15334406     Source Type: Journal    
DOI: 10.1056/NEJMoa1613512     Document Type: Article

References (20)

1. Chhatwal J, Wang X, Ayer T, et al. Hepatitis C disease burden in the United States in the era of oral direct-acting antivirals. Hepatology 2016; 64: 1442-50.
2. Asselah T, Boyer N, Saadoun D, Martinot-Peignoux M, Marcellin P. Directacting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives. Liver Int 2016; 36: Suppl 1: 47-57.
3. Naggie S, Muir AJ. Oral combination therapies for hepatitis C virus infection: successes, challenges, and unmet needs. Annu Rev Med 2017; 68: 345-58.
4. World Health Organization. Hepatitis C: fact sheet. July 2016 (http://www.who.int/mediacentre/factsheets/fs164/en/).
5. Sarrazin C. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol 2016; 64: 486-504.
6. Sovaldi (sofosbuvir) tablets: U.S. prescribing information. Foster City, CA: Gilead Sciences, 2014 (http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi-pi.pdf).
7. Harvoni (ledipasvir and sofosbuvir) tablets: U.S. prescribing information. Foster City, CA: Gilead Sciences, 2015 (http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/harvoni/harvoni-pi.pdf).
8. Epclusa (sofosbuvir and velpatasvir) tablets: U.S. prescribing information. Foster City, CA: Gilead Sciences, 2016 (https://www.gilead.com/~/media/files/pdfs/medicines/liver-disease/epclusa/epclusa-pi.pdf?la=en).
9. Lawitz E, Freilich B, Link J, et al. A phase 1, randomized, dose-ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1-4 hepatitis C virus. J Viral Hepat 2015; 22: 1011-9.
10. Feld JJ, Jacobson IM, Hézode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med 2015; 373: 2599-607.
11. Foster GR, Afdhal N, Roberts SK, et al. Sofosbuvir and velpatasvir for HCV genotype 2 and 3 infection. N Engl J Med 2015; 373: 2608-17.
12. Taylor J, Appleby T, Barauskas O, et al. P0899: preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857. J Hepatol 2015; 62: Suppl: S681.
13. Kirby B, Yang J, Yang C, et al. P0861: evaluation of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857 in healthy volunteers. J Hepatol 2015; 62: Suppl: S663.
14. Rodriguez-Torres M, Glass S, Hill J, et al. GS-9857 in patients with chronic hepatitis C virus genotype 1-4 infection: a randomized, double-blind, dose-ranging phase 1 study. J Viral Hepat 2016; 23: 614-22.
15. Gane EJ, Schwabe C, Hyland RH, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naïve or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology 2016; 151(3): 448-456.e1.
16. Lawitz E, Reau N, Hinestrosa F, et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with genotype 1 hepatitis C virus infection in an open-label, phase 2 trial. Gastroenterology 2016; 151(5): 893-901.e1.
17. Gane EJ, Kowdley KV, Pound D, et al. Efficacy of sofosbuvir, velpatasvir, and GS-9857 in patients with hepatitis C virus genotype 2, 3, 4, or 6 infections in an open-label, phase 2 trial. Gastroenterology 2016; 151: 902-9.
18. Aghemo A, Buti M. Hepatitis C therapy: game over! Gastroenterology 2016; 151: 795-8.
19. Esposito I, Trinks J, Soriano V. Hepatitis C virus resistance to the new directacting antivirals. Expert Opin Drug Metab Toxicol 2016; 12: 1197-209.
20. Banerjee D, Reddy KR. Review article: safety and tolerability of direct-acting anti-viral agents in the new era of hepatitis C therapy. Aliment Pharmacol Ther 2016; 43: 674-96.